home / stock / bvs / bvs news

BVS News and Press, Bioventus Inc. From 04/12/21

Stock Information
Company Name: Bioventus Inc.
Stock Symbol: BVS
Market: NASDAQ
Website: bioventus.com
Menu
BVS BVS Quote BVS Short BVS News BVS Articles BVS Message Board
Get BVS Alerts

News, Short Squeeze, Breakout and More Instantly...
BVS - Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after th...
BVS - Insider Weekends: Jack Hightower Purchases Nearly $2 Million Of HighPeak Energy

Insider buying decreased significantly last week. Notable Insider Buys: HighPeak Energy, Inc., William Penn Bancorporation, Bioventus Inc., Athenex, Inc., Sensei Biotherapeutics, Inc. Notable Insider Sells: Facebook, Inc., Ulta Beauty, Inc., Guardant Health, Inc., Applied Material...

BVS - Bioventus acquires Bioness for $45M up-front consideration

Bioventus (BVS) acquires Bioness, a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation therapy and premium rehabilitation solutions.The transaction value is for $45M in up-front consideration, with up to $65M of conting...

BVS - Bioventus Acquires Bioness, Inc.

DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc . (“Bioness”), a global leader in neuromodulation and ...
BVS - Bioventus EPS beats by $0.07, beats on revenue

Bioventus (BVS): Q4 GAAP EPS of $0.10 beats by $0.07.Revenue of $98.59M (+1.1% Y/Y) beats by $0.51M.Press Release For further details see: Bioventus EPS beats by $0.07, beats on revenue

BVS - Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance

DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the fourth quarter and year ended December 31, 2020. This press r...

BVS - Bioventus enrolls first patient in early-stage MOTYS osteoarthritis trial

Bioventus (BVS) reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study evaluating the safety and efficacy of MOTYS ((PTP-001)) to treat osteoarthritis ((OA)) of the knee.Current treatments for knee OA are limited to corticosteroids ...
BVS - Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS(TM) (PTP-001) for the Treatment of Knee OA

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalatio...

Previous 10 Next 10